Microsoft's 2029 quantum supercomputer ambitions may have hit a roadblock, as critics claim the company's 2025 quantum ...
June 2026 TIOBE Index shows Python slipping below 19%, C++ moving back ahead of Java, and Rust reaching #12 as Paul Jansen ...
Alzheimer's disease is a neurodegenerative disease characterized by a progressive decline in mental functions and memory loss. Along with frontotemporal dementia and some other neurodegenerative ...
Nvidia CEO Jensen Huang gave a media interview after the "trillion-dollar dinner" in Taipei, Taiwan, on May 28, commenting on topics including competition in the artificial intelligence (AI) industry, ...
When Huawei unveiled its "Tau (τ) Scaling Law" at ISCAS 2026 in Shanghai, the announcement signalled more than another chip architecture update. It marked China's most ambitious attempt yet to ...
For five decades, chipmakers chased Moore's Law by cramming smaller transistors onto silicon. That cadence has been slowing across the industry. For Huawei, it stopped entirely. He Tingbo said ...
Macquarie's Eugene Hsiao discusses the end of Moore's Law after Huawei introduces Tau Scaling Law. He sees convergence of chipmaking paths as the race for more cutting-edge chips continue. Meanwhile, ...
He Tingbo used a Shanghai keynote to argue that cutting signal-propagation time, not shrinking transistors, is the new frontier, and that Huawei has been quietly building chips around the idea for six ...
Huawei is proposing a new way to keep the semiconductor industry moving forward at a time when making smaller and smaller chips is becoming increasingly difficult. At the International Circuit Systems ...
In real life, Tau Ceti is the name of a star, approximately 12 light years away from Earth. It was first catalogued in 1603 by Johann Bayer, and as of this writing, astronomers estimate it has four ...
Biogen and Ionis plan to share data at the Alzheimer’s Association International Conference in July. (Getty Images) A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed ...
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results